CTLA4 and myeloproliferative neoplasm: Immune checkpoint blockade using anti‐PD1 and anti‐CTLA4 monoclonal antibodies induced mutant CRT‐specific T cell responses in blood samples from MPN patients, indicating that PD1 and CTLA4 expression suppress MPN‐specific T cell responses (both CD4+ or CD8+).84